Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perlegen Sciences is to assist Merck & Co in conducting a high-density whole genome analysis of more than 1,000 individuals with important clinical characteristics. The work may give Merck important leads in the discovery of new drugs.
Subscribe to our email newsletter
Using Affymetrix GeneChip technology including the GeneChip Human Mapping 500K Array Set, Perlegen scientists will assay up to 675,000 unique genetic variations (also called single nucleotide polymorphisms or SNPs) in DNA samples provided by Merck.
Perlegen will utilize its high capacity SNP genotyping capability to rapidly generate extremely dense DNA variation data that can be integrated with other large datasets Merck has generated by molecular profiling clinically important tissue samples internally. Terms of the agreement were not disclosed.
“We are pleased to work with Merck scientists in identifying DNA variations that may underlie biological mechanisms important to their drug discovery efforts,” said Brad Margus, CEO of Perlegen. “It was an honor to have been selected by Merck for this important project.”